Mylan N.V. announced the U.S. launch of Azacitidine for Injection, 100 mg/vial, a generic version of Celgene’s Vidaza Injection. Mylan received final approval from FDA for its Abbreviated New Drug Application for this product. Azacitidine for Injection is a nucleoside metabolic inhibitor indicated for the treatment of the five French-American-British subtypes of myelodysplastic syndrome. jQuery(document).ready(function(){... […]
The Department of Defense Lung Cancer Research Program is accepting preapplications and letters of intent for concept award grant, worth up to $100,000 for one year, for direct costs not related directly to clinical trials.
A study reviewing trends in oncology found that more than 20 tumor types are being treated with one or more of the 70 cancer treatments that have been launched in the past five years.
The American Society of Clinical Oncology published an updated framework for assessing the relative value of cancer therapies that have been compared in clinical trials.
The University of Maryland Marlene and Stewart Greenebaum Cancer Center has earned a designation as an NCI-designated Comprehensive Cancer Center. The center announced the NCI designation May 31.
NCI CTEP-Approved Trials for the Month of May
Introducing palliative care shortly after a cancer diagnosis results in better quality of life and fewer depression symptoms for family caregivers, according to a randomized clinical trial.
A meta-analysis of 346 phase I clinical trials, involving more than 13,000 patients, found that selecting treatment based on a tumor's molecular characteristics led to significantly better outcomes.
An independent data monitoring committee found that a phase III trial of LEE011 (ribociclib) had met its primary endpoint of improving progression-free survival in patients with advanced breast cancer, and recommended that it be stopped early.
WT1 Vaccine Doubles PFS in Phase II Trial
